News

News

Emyria enters into data deal with Zelira to support Autism Spectrum Disorder trial

Emyria enters into data deal with Zelira to support Autism Spectrum Disorder trial

The observational trial will be one of the largest medical cannabis studies ever undertaken involving a specific range of products in patients diagnosed with Autism Spectrum Disorder (ASD).

 

Read the full announcement here

Have Questions?

If you have any question, please feel free to get in touch with us.

Call 1300 436 363Contact